Answers are grounded in this paper and cite their sources.
TP53-mutated acute myeloid leukemia (AML) accounts for approximately 5%-10% of newly diagnosed AML. It is characterized by enrichment of complex karyotypes, genomic instability, and treatment resistance, resulting in an extremely poor overall prognosis. Although intensive chemotherapy and hypomethylating agents (HMAs) combined with venetoclax can induce remission in some patients, remission duration and long-term survival remain unsatisfactory; novel treatments targeting the p53 pathway, immune microenvironment, and metabolic vulnerabilities have likewise not achieved a breakthrough. Recent studies indicate that the biological effects of TP53 abnormalities depend not only on the mutation itself but also on allelic status, clonal evolution, cytogenetic background, and the immune and metabolic microenvironments. This review summarizes the molecular features, clonal evolution, immune microenvironment, and metabolic reprogramming of TP53-mutated AML; its biological mechanisms, prognostic implications, and therapeutic advances; and the major challenges of allogeneic hematopoietic stem cell transplantation and novel therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: